Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations

Vito Chiantera, Anna Fagotti, Gabriella Ferrandina, Andrea Di Giorgio, Valerio Gallotta, Agostino Maria De Rose, Giuseppe Vizzielli, Gian Franco Zannoni, Barbara Costantini, Carmine Conte, Giovanni Scambia

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85.9%). The median number of HCLNs removed was 6 (range 1–18). Histopathologic evaluation was able to identify HCLN metastasis in 45 (52.9%) of the 85 cases. No difference in the rate of surgical morbidity according to pathologic status of HCLN was observed. As of December 2016, the median follow-up period was 36 months (range 6–54 months). Recurrence of disease was observed in 35 (41.2%) of the 85 cases. Relapse of disease most frequently occurred for the patients with metastatic HCLN involvement (65.7%) compared with the patients who had no HCLN involvement (34.3%) (p = 0.048). The median progression-free survival values were 16 months (95% confidence interval [CI], 12–19 months) for the patients with metastatic HCLNs and 22 months (95% CI, 12–19 months) for the patients with no HCLN involvement (p = 0.035). Conclusions: The study confirmed that HCLN surgery is feasible with acceptable morbidities for patients with advanced OC. Metastatic HCLNs are a marker of disease severity associated with worst oncologic outcome.
Lingua originaleEnglish
pagine (da-a)-
Numero di pagine9
RivistaAnnals of Surgical Oncology
Stato di pubblicazionePublished - 2017

Fingerprint

Ovarian Neoplasms
Lymph Nodes
Morbidity
Confidence Intervals
Recurrence
Surgical Pathology
Disease-Free Survival
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cita questo

Chiantera, V., Fagotti, A., Ferrandina, G., Di Giorgio, A., Gallotta, V., De Rose, A. M., ... Scambia, G. (2017). Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations. Annals of Surgical Oncology, -.

Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations. / Chiantera, Vito; Fagotti, Anna; Ferrandina, Gabriella; Di Giorgio, Andrea; Gallotta, Valerio; De Rose, Agostino Maria; Vizzielli, Giuseppe; Zannoni, Gian Franco; Costantini, Barbara; Conte, Carmine; Scambia, Giovanni.

In: Annals of Surgical Oncology, 2017, pag. -.

Risultato della ricerca: Article

Chiantera, V, Fagotti, A, Ferrandina, G, Di Giorgio, A, Gallotta, V, De Rose, AM, Vizzielli, G, Zannoni, GF, Costantini, B, Conte, C & Scambia, G 2017, 'Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations', Annals of Surgical Oncology, pagg. -.
Chiantera, Vito ; Fagotti, Anna ; Ferrandina, Gabriella ; Di Giorgio, Andrea ; Gallotta, Valerio ; De Rose, Agostino Maria ; Vizzielli, Giuseppe ; Zannoni, Gian Franco ; Costantini, Barbara ; Conte, Carmine ; Scambia, Giovanni. / Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations. In: Annals of Surgical Oncology. 2017 ; pagg. -.
@article{d8220b71650d474582d7f7c20eab3771,
title = "Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations",
abstract = "Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85.9{\%}). The median number of HCLNs removed was 6 (range 1–18). Histopathologic evaluation was able to identify HCLN metastasis in 45 (52.9{\%}) of the 85 cases. No difference in the rate of surgical morbidity according to pathologic status of HCLN was observed. As of December 2016, the median follow-up period was 36 months (range 6–54 months). Recurrence of disease was observed in 35 (41.2{\%}) of the 85 cases. Relapse of disease most frequently occurred for the patients with metastatic HCLN involvement (65.7{\%}) compared with the patients who had no HCLN involvement (34.3{\%}) (p = 0.048). The median progression-free survival values were 16 months (95{\%} confidence interval [CI], 12–19 months) for the patients with metastatic HCLNs and 22 months (95{\%} CI, 12–19 months) for the patients with no HCLN involvement (p = 0.035). Conclusions: The study confirmed that HCLN surgery is feasible with acceptable morbidities for patients with advanced OC. Metastatic HCLNs are a marker of disease severity associated with worst oncologic outcome.",
author = "Vito Chiantera and Anna Fagotti and Gabriella Ferrandina and {Di Giorgio}, Andrea and Valerio Gallotta and {De Rose}, {Agostino Maria} and Giuseppe Vizzielli and Zannoni, {Gian Franco} and Barbara Costantini and Carmine Conte and Giovanni Scambia",
year = "2017",
language = "English",
pages = "--",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations

AU - Chiantera, Vito

AU - Fagotti, Anna

AU - Ferrandina, Gabriella

AU - Di Giorgio, Andrea

AU - Gallotta, Valerio

AU - De Rose, Agostino Maria

AU - Vizzielli, Giuseppe

AU - Zannoni, Gian Franco

AU - Costantini, Barbara

AU - Conte, Carmine

AU - Scambia, Giovanni

PY - 2017

Y1 - 2017

N2 - Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85.9%). The median number of HCLNs removed was 6 (range 1–18). Histopathologic evaluation was able to identify HCLN metastasis in 45 (52.9%) of the 85 cases. No difference in the rate of surgical morbidity according to pathologic status of HCLN was observed. As of December 2016, the median follow-up period was 36 months (range 6–54 months). Recurrence of disease was observed in 35 (41.2%) of the 85 cases. Relapse of disease most frequently occurred for the patients with metastatic HCLN involvement (65.7%) compared with the patients who had no HCLN involvement (34.3%) (p = 0.048). The median progression-free survival values were 16 months (95% confidence interval [CI], 12–19 months) for the patients with metastatic HCLNs and 22 months (95% CI, 12–19 months) for the patients with no HCLN involvement (p = 0.035). Conclusions: The study confirmed that HCLN surgery is feasible with acceptable morbidities for patients with advanced OC. Metastatic HCLNs are a marker of disease severity associated with worst oncologic outcome.

AB - Background: The study aimed too investigate the rate of hepatoceliac lymph node (HCLN) involvement, as well as its association with clinicopathologic features, together with morbidity of HCLN resection and the prognostic impact of metastatic HCLN status on patients with advanced ovarian cancer (OC) undergoing cytoreductive surgery. Methods: All consecutive patients with stages 3c to 4 epithelial OC who underwent HCLN surgery from January 2010 to September 2016 were analyzed for surgical procedures, pathology, and oncologic outcomes. Results: During the study period, 85 patients underwent HCLN resection. Absence of visible tumor at the end of surgery was documented for 73 of the patients (85.9%). The median number of HCLNs removed was 6 (range 1–18). Histopathologic evaluation was able to identify HCLN metastasis in 45 (52.9%) of the 85 cases. No difference in the rate of surgical morbidity according to pathologic status of HCLN was observed. As of December 2016, the median follow-up period was 36 months (range 6–54 months). Recurrence of disease was observed in 35 (41.2%) of the 85 cases. Relapse of disease most frequently occurred for the patients with metastatic HCLN involvement (65.7%) compared with the patients who had no HCLN involvement (34.3%) (p = 0.048). The median progression-free survival values were 16 months (95% confidence interval [CI], 12–19 months) for the patients with metastatic HCLNs and 22 months (95% CI, 12–19 months) for the patients with no HCLN involvement (p = 0.035). Conclusions: The study confirmed that HCLN surgery is feasible with acceptable morbidities for patients with advanced OC. Metastatic HCLNs are a marker of disease severity associated with worst oncologic outcome.

UR - http://hdl.handle.net/10447/239439

M3 - Article

SP - -

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -